⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
If you are taking semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro), understanding how these medications work in your body does more than satisfy curiosity. It helps you make better decisions about timing, food choices, side effect management, and realistic expectations. It also helps you have more informed conversations with your endocrinologist.
This guide explains the pharmacology of GLP-1 receptor agonists in plain language — for Indian patients navigating these powerful medications for the first time.
Consult your healthcare provider before starting any medication or making changes to your treatment plan.
GLP-1 stands for Glucagon-Like Peptide-1 — a hormone your gut produces naturally every time you eat. Specifically, it is secreted by L-cells in the small intestine and colon within minutes of food entering your digestive system.
Natural GLP-1 does five things:
Here is the catch: your body destroys natural GLP-1 within 1–2 minutes of it being released. An enzyme called DPP-4 (dipeptidyl peptidase-4) breaks it down almost immediately. This is why natural GLP-1 cannot be used as a medication — it would be degraded before it could do anything useful.
This is also why an entire class of diabetes drugs (DPP-4 inhibitors like sitagliptin / Januvia) works by blocking DPP-4 — to let your natural GLP-1 last longer.
Pharmaceutical GLP-1 receptor agonists (GLP-1 RAs) are engineered molecules that:
Semaglutide has a half-life of approximately 7 days — meaning half the drug is still in your system a week after injection. This is why a single weekly injection maintains relatively stable blood levels. The drug is also bound to albumin (a blood protein) which further slows its clearance.
Tirzepatide is structurally similar to semaglutide but adds a twist — it also activates the GIP receptor (Glucose-Dependent Insulinotropic Polypeptide), making it a dual agonist. This GIP activation amplifies the insulin response and — importantly — may cause more weight loss than GLP-1 alone. This is the main reason tirzepatide (Mounjaro) tends to produce greater weight loss than semaglutide (Ozempic) in head-to-head comparisons.
GLP-1 receptors exist in the hypothalamus (the brain's appetite control centre) and in the brainstem (which processes nausea and fullness signals). When semaglutide binds these receptors:
For Indian patients, this often means that the appeal of ghee-heavy dishes, mithai, and late-night snacking genuinely decreases — not because you are forcing yourself, but because the brain's reward response is changed.
GLP-1 significantly slows gastric emptying — the rate at which food moves from the stomach to the small intestine. On semaglutide, this can be slowed by 30–50%.
Why this helps: Food exiting the stomach slowly produces a gentler glucose rise after meals, reducing the post-meal blood sugar spike that is particularly problematic in Indian high-carbohydrate diets.
Why this causes side effects: When food sits in the stomach longer, nausea, bloating, and a feeling of heaviness are common — especially with fat-rich meals. This is why fatty Indian foods (ghee-heavy curries, puri, paratha) are harder to tolerate on GLP-1.
GLP-1 medications act directly on pancreatic beta cells to stimulate insulin release — but only when blood glucose is elevated. This glucose-dependency is critical: unlike sulfonylureas (glipizide, glibenclamide), GLP-1 RAs do not cause the pancreas to release insulin when blood sugar is already normal, which dramatically reduces hypoglycaemia risk.
Simultaneously, GLP-1 suppresses glucagon from alpha cells. Since glucagon tells the liver "release stored glucose," blocking it prevents unwanted glucose release — especially in the fasting state and overnight.
GLP-1 receptors in the liver reduce hepatic glucose production — the liver's tendency to manufacture and release glucose even when blood sugar is already adequate. This is a major driver of elevated fasting blood sugar in type 2 diabetes, especially in Indians who tend to have higher rates of hepatic insulin resistance.
Reduced hepatic glucose output explains why GLP-1 medications improve fasting blood sugar readings even overnight — not just post-meal values.
GLP-1 receptors exist in cardiac muscle and kidney tissue. Clinical trials — including the LEADER trial (liraglutide) and SUSTAIN-6 (semaglutide) — demonstrated 20–26% reductions in major cardiovascular events (heart attack, stroke, cardiovascular death) in high-risk patients.
Mechanistically, GLP-1 drugs appear to:
For Indian patients, who have disproportionately high rates of cardiovascular disease at younger ages and lower BMI compared to Western populations, these cardioprotective effects are particularly important and increasingly driving prescriptions for non-diabetic Indian patients with metabolic syndrome.
| Feature | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro) |
|---|---|---|
| Receptor targets | GLP-1 only | GLP-1 + GIP (dual) |
| Weekly weight loss (average) | 1–1.5 kg/month | 1.5–2 kg/month |
| Available in India (as of 2026) | Yes (Ozempic, Rybelsus, Wegovy) | Yes (Mounjaro) |
| Approximate monthly cost (India) | ₹8,000–₹18,000 | ₹14,000–₹28,000 |
| Nausea severity | Moderate | Moderate to moderate-high |
| Maximum approved dose | 2.4 mg/week (Wegovy) | 15 mg/week |
The GIP receptor activation in tirzepatide appears to enhance insulin secretion through a different pathway than GLP-1 and may also directly affect fat cell metabolism — leading to greater fat loss, particularly visceral (belly) fat.
When you inject semaglutide weekly, the drug does not immediately reach maximum concentration. It builds up over 4–5 weeks until it reaches steady state — a stable blood level maintained by the balance between weekly injection and ongoing clearance.
This explains several things Indian patients often ask about:
Month 1 (0.25 mg or 2.5 mg): Little weight loss (this is the adjustment phase). Primary goal: tolerability. Some patients notice reduced appetite already.
Month 2 (0.5 mg or 5 mg): Appetite suppression becomes clear. Most patients see 2–4% body weight loss. Blood sugar begins improving.
Month 3 (1 mg or 7.5 mg): Weight loss accelerates. Many patients report food "noise" reducing. Side effects generally stabilise.
Months 4–6: Peak rate of weight loss for many patients. Average 10–15% body weight loss by 6 months on semaglutide 2.4 mg; slightly higher on tirzepatide 10–15 mg.
After 12 months: Weight loss slows and plateaus for most patients. The medication is now primarily maintaining your lower weight and metabolic improvements, not driving further large losses.
Why you cannot eat ghee-heavy food: The slowed gastric emptying means fat-rich food lingers in the stomach for hours. The stomach signals distress, causing nausea and vomiting.
Why you feel full on very small portions: GLP-1 activates stretch receptors in the stomach earlier and sends satiety signals to the brain simultaneously from two directions.
Why some people feel less emotionally connected to food: The drug genuinely alters the brain's reward processing of food. This is pharmacological, not psychological — and it is why "food noise reduction" is so commonly reported.
Why blood sugar improves even without weight loss: The pancreatic, hepatic, and gastric effects all improve glucose metabolism independently of weight change.
Q: If my body already makes GLP-1 naturally, why does the drug work so much better? Natural GLP-1 is destroyed within 2 minutes and only responds to each meal. Drug-based GLP-1 RAs are present continuously at high concentrations, activating receptors 24 hours a day, 7 days a week — a fundamentally different pharmacological profile.
Q: Can I become dependent on GLP-1 medications? These are not addictive medications in the pharmacological sense. However, if you stop them, the natural weight-regulation effects disappear and weight typically returns within 1 year. This is why they are often described as long-term or lifelong treatments for chronic obesity, similar to blood pressure medication.
Q: Is tirzepatide always better than semaglutide? On average, tirzepatide produces more weight loss. But individual responses vary significantly — some patients lose more on semaglutide. Tirzepatide is also substantially more expensive in India. Cost, tolerability, and individual response all matter.
Q: Will GLP-1 medications affect my other medications? GLP-1 slows gastric emptying, which changes how quickly other oral medications are absorbed. Discuss all current medications with your doctor before starting GLP-1 therapy, particularly thyroid medication (levothyroxine), oral contraceptives, and anticoagulants.
Consult your healthcare provider before starting any medication or making changes to your treatment plan.
